Mads Hvid Poulsen1,2, Morten Frost3,4, Bo Abrahamsen5,6, Oke Gerke7, Steen Walter1,8, Lars Lund1,2,8. 1. a Department of Urology , Odense University Hospital , Odense , Denmark. 2. b Academy of Geriatric Cancer Research (AgeCare) , Odense University Hospital , Odense , Denmark. 3. c Department of Endocrinology , Odense University Hospital , Odense , Denmark. 4. d Steno Diabetes Center Odense , Odense University Hospital , Odense , Denmark. 5. e Department of Medicine and Endocrinology , Holbaek Hospital , Holbaek , Denmark. 6. f OPEN, Department of Clinical Research , University of Southern Denmark , Odense , Denmark. 7. g Department of Nuclear Medicine , Odense University Hospital , Odense , Denmark. 8. h Department of Clinical Research , University of Southern Denmark , Odense , Denmark.
Abstract
Objective: To analyze the prevalence of osteoporosis during androgen deprivation therapy (A.D.T.). Background: Treatment and prognosis of prostate cancer necessitate management of long-term consequences of A.D.T., including accelerated bone loss resulting in osteoporosis; osteoporotic fractures are associated with excess morbidity and mortality. Patients and methods: Patients with prostate cancer awaiting initiation of A.D.T. were consecutively included from the daily clinic. They were followed every 6 months for 2 years. The study consisted of questionnaires, blood and urine samples and a D.X.A. scan every 6 months and yearly bone scintigraphy. A.D.T. was given as L.H.R.H. agonists, L.H.R.H. antagonists or orchiectomy. None of the patients had received prior A.D.T. or osteoporosis treatment. Results: A total of 105 individuals were included. The mean age was 70 years, median PSA level was 30.5 µg/L and median Gleason score was 7. During the study, the prevalence of osteoporosis rose from 10% at inclusion to 22% after the 2 years of follow-up and the prevalence of normal bone mineral density (B.M.D.) decreased from 32% to 8%. Osteoporotic fractures were prevalent; six patients had a clinical vertebral fracture and two patients had a hip fracture. One patient died after his hip fracture. Conclusion: After 2 years of A.D.T. the vast majority of prostate cancer patients will have osteoporosis or osteopenia. A rigorous observation strategy did not appear to prevent osteoporotic fractures. A new strategy to reduce A.D.T. induced osteoporotic fractures is mandatory.
Objective: To analyze the prevalence of osteoporosis during androgen deprivation therapy (A.D.T.). Background: Treatment and prognosis of prostate cancer necessitate management of long-term consequences of A.D.T., including accelerated bone loss resulting in osteoporosis; osteoporotic fractures are associated with excess morbidity and mortality. Patients and methods: Patients with prostate cancer awaiting initiation of A.D.T. were consecutively included from the daily clinic. They were followed every 6 months for 2 years. The study consisted of questionnaires, blood and urine samples and a D.X.A. scan every 6 months and yearly bone scintigraphy. A.D.T. was given as L.H.R.H. agonists, L.H.R.H. antagonists or orchiectomy. None of the patients had received prior A.D.T. or osteoporosis treatment. Results: A total of 105 individuals were included. The mean age was 70 years, median PSA level was 30.5 µg/L and median Gleason score was 7. During the study, the prevalence of osteoporosis rose from 10% at inclusion to 22% after the 2 years of follow-up and the prevalence of normal bone mineral density (B.M.D.) decreased from 32% to 8%. Osteoporotic fractures were prevalent; six patients had a clinical vertebral fracture and two patients had a hip fracture. One patientdied after his hip fracture. Conclusion: After 2 years of A.D.T. the vast majority of prostate cancerpatients will have osteoporosis or osteopenia. A rigorous observation strategy did not appear to prevent osteoporotic fractures. A new strategy to reduce A.D.T. induced osteoporotic fractures is mandatory.
Authors: Schroder Sattar; Kristen R Haase; Koen Milisen; Diane Campbell; Soo Jung Kim; Haji Chalchal; Cindy Kenis Journal: Can Oncol Nurs J Date: 2021-11-01
Authors: Naim M Maalouf; Avneesh Chhabra; Jason Zafereo; Ross Querry; Dwight A Towler; Uma J Thakur; Joseph Frankl; John R Poindexter; Bayan Mogharrabi; May Xac; Orhan K Öz; Craig D Rubin Journal: JBMR Plus Date: 2021-11-15
Authors: Lisa Umlauff; Manuel Weber; Nils Freitag; Ciaran M Fairman; Axel Heidenreich; Wilhelm Bloch; Moritz Schumann Journal: Prostate Cancer Prostatic Dis Date: 2021-06-30 Impact factor: 5.455